Actively Recruiting
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Led by Shanghai Gynecologic Oncology Group · Updated on 2025-11-19
94
Participants Needed
1
Research Sites
197 weeks
Total Duration
On this page
Sponsors
S
Shanghai Gynecologic Oncology Group
Lead Sponsor
F
Fudan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
CONDITIONS
Official Title
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years to 75 years
- Pathologically confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma, or platinum-sensitive relapsed disease with no more than 4 prior therapy lines
- Hepato-celiac lymph node metastases diagnosed by imaging and confirmed by surgical findings
- Complete tumor resection is considered feasible by experienced surgeons before surgery
- Allowed 1 to 3 cycles of neoadjuvant chemotherapy in primary treatment cases
- Platinum-sensitive relapse defined as a platinum-free interval of 6 months or more
- ASA score between 1 and 2
- ECOG performance status between 0 and 2
- Adequate bone marrow, liver, and kidney function to undergo chemotherapy and surgery, including specific blood count and organ function thresholds
- Willingness to comply with study protocol and follow-up
- Provided written informed consent
You will not qualify if you...
- Non-epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma
- Low-grade carcinoma
- Mucinous ovarian cancer
- Infeasibility of complete tumor resection based on preoperative evaluation
- Unresectable lung or liver metastases, multiple thoracic lymph node metastases, brain or bone metastases
- Carcinomatosis on small bowel mesentery or intestinal wall making optimal surgery impossible
- Disease progression after neoadjuvant chemotherapy in primary treatment
- Other cancers diagnosed within 5 years except carcinoma in situ or breast cancer without relapse
- Medical conditions that contraindicate surgery or chemotherapy and could affect protocol adherence
- Religious, psychological, or other factors interfering with informed consent, compliance, or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital, Fudan University
Shanghai, China
Actively Recruiting
Research Team
L
Libing Xiang
CONTACT
R
Rong Jiang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here